Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.75
ACRX's Cash to Debt is ranked higher than
73% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. ACRX: 3.75 )
ACRX' s 10-Year Cash to Debt Range
Min: 0.31   Max: No Debt
Current: 3.75

Equity to Asset 0.55
ACRX's Equity to Asset is ranked higher than
62% of the 728 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. ACRX: 0.55 )
ACRX' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.69
Current: 0.55

-0.01
0.69
F-Score: 4
Z-Score: 2.64
M-Score: 4.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -22.60
ACRX's Operating margin (%) is ranked higher than
51% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. ACRX: -22.60 )
ACRX' s 10-Year Operating margin (%) Range
Min: -1805.22   Max: -22.6
Current: -22.6

-1805.22
-22.6
Net-margin (%) -79.40
ACRX's Net-margin (%) is ranked lower than
52% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. ACRX: -79.40 )
ACRX' s 10-Year Net-margin (%) Range
Min: -1875.09   Max: -79.4
Current: -79.4

-1875.09
-79.4
ROE (%) -32.02
ACRX's ROE (%) is ranked lower than
51% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. ACRX: -32.02 )
ACRX' s 10-Year ROE (%) Range
Min: -115.07   Max: -32.02
Current: -32.02

-115.07
-32.02
ROA (%) -21.29
ACRX's ROA (%) is ranked lower than
51% of the 777 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. ACRX: -21.29 )
ACRX' s 10-Year ROA (%) Range
Min: -210.01   Max: -21.29
Current: -21.29

-210.01
-21.29
ROC (Joel Greenblatt) (%) -128.73
ACRX's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.60 vs. ACRX: -128.73 )
ACRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1486.8   Max: -128.73
Current: -128.73

-1486.8
-128.73
EBITDA Growth (%) -68.80
ACRX's EBITDA Growth (%) is ranked lower than
54% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. ACRX: -68.80 )
ACRX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -64.9
Current: -68.8

EPS Growth (%) -70.00
ACRX's EPS Growth (%) is ranked lower than
53% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ACRX: -70.00 )
ACRX' s 10-Year EPS Growth (%) Range
Min: 0   Max: -64.9
Current: -70

» ACRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

ACRX Guru Trades in Q4 2012

Louis Moore Bacon 150,000 sh (New)
» More
Q1 2013

ACRX Guru Trades in Q1 2013

Louis Moore Bacon Sold Out
» More
Q1 2014

ACRX Guru Trades in Q1 2014

Louis Moore Bacon 36,000 sh (New)
» More
Q2 2014

ACRX Guru Trades in Q2 2014

Louis Moore Bacon 50,000 sh (+38.89%)
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.59
ACRX's P/B is ranked lower than
52% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. ACRX: 5.59 )
ACRX' s 10-Year P/B Range
Min: 2.16   Max: 78
Current: 5.59

2.16
78
EV-to-EBIT -25.00
ACRX's EV-to-EBIT is ranked higher than
53% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. ACRX: -25.00 )
ACRX' s 10-Year EV-to-EBIT Range
Min: 4.2   Max: 9.4
Current: -25

4.2
9.4
Current Ratio 10.67
ACRX's Current Ratio is ranked higher than
94% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. ACRX: 10.67 )
ACRX' s 10-Year Current Ratio Range
Min: 0.43   Max: 20.39
Current: 10.67

0.43
20.39
Quick Ratio 10.67
ACRX's Quick Ratio is ranked higher than
95% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. ACRX: 10.67 )
ACRX' s 10-Year Quick Ratio Range
Min: 0.43   Max: 20.39
Current: 10.67

0.43
20.39

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.50
ACRX's Price/Net Cash is ranked higher than
96% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ACRX: 6.50 )
ACRX' s 10-Year Price/Net Cash Range
Min: 2.2   Max: 25
Current: 6.5

2.2
25
Price/Net Current Asset Value 6.50
ACRX's Price/Net Current Asset Value is ranked higher than
94% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ACRX: 6.50 )
ACRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.2   Max: 25
Current: 6.5

2.2
25
Price/Tangible Book 5.59
ACRX's Price/Tangible Book is ranked higher than
67% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. ACRX: 5.59 )
ACRX' s 10-Year Price/Tangible Book Range
Min: 2.08   Max: 57.94
Current: 5.59

2.08
57.94

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:R5X.Germany
Acelrx Pharmaceuticals Inc. is a specialty pharmaceutical company involved in the development and commercialization of therapies for the treatment of acute and breakthrough pain.
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Aug 29 2014
AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events Aug 27 2014
The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks Aug 26 2014
ACELRX PHARMACEUTICALS INC Financials Aug 19 2014
ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 11 2014
AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results Aug 11 2014
Q2 2014 AcelRx Pharmaceuticals, Inc. Earnings Release - After Market Close Aug 11 2014
AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events Aug 08 2014
AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on... Aug 07 2014
AcelRx Pharmaceuticals (ACRX) Soars: Stock Adds 6.8% in Session Aug 01 2014
Today's Dead Cat Bounce Stock: AcelRx Pharmaceuticals (ACRX) Jul 29 2014
Dow, S&P 500 inch up, while Nasdaq, Russell 2000 slip: stock market live blog recap Jul 28 2014
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 28 2014
AcelRx Pharma Plunges After FDA Rejects Device Jul 28 2014
Why AcelRx Pharmaceuticals (ACRX) Stock Is Plummeting Today Jul 28 2014
FDA Rejects AcelRx Painkiller Dispensing Device (Update) Jul 28 2014
[video] Mon., July 28: Family Dollar Among Stocks to Watch Jul 28 2014
AcelRX Selling Off Sharply On FDA Reexamination Jul 28 2014
AcelRx stock plunges after FDA rejects pain drug device Jul 28 2014
AcelRx downgraded by Canaccord Genuity Jul 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK